Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

131.49 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Beat the Nasdaq With This Cash-Gushing Dividend Stock
The company is performing well despite recently losing its biggest growth driver. 
Via The Motley Fool
P/E Ratio Insights for Abbott Laboratories
Via Benzinga
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
These companies' longtime shareholders have generally been rewarded. 
Via The Motley Fool
MarketBeat Week in Review – 10/14 - 10/18
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
The Dow Jones and S&P 500 hit highs as they extended weekly win streaks. 
Via Investor's Business Daily
Topics Stocks
Is Abbott Laboratories Stock a Buy?
The healthcare stock is lagging the market this year. 
Via The Motley Fool
Price Over Earnings Overview: Abbott Laboratories
Via Benzinga
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
Abbott Laboratories reported Q3 sales of $10.64 billion, driven by 8.2% organic growth in medical devices. Adjusted EPS for 2024 projected at $4.64-$4.70, with expectations of double-digit growth... 
Via Benzinga
These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings
Via Benzinga
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says. 
Via Benzinga
Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices
Medical devices led organic sales growth. 
Via Investor's Business Daily
A Glimpse of Abbott Laboratories's Earnings Potential
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock
Via Benzinga
Why Abbott Laboratories Stock Was a Winner on Wednesday
Investors bumped its shares higher following a decent, if unspectacular, earnings report. 
Via The Motley Fool
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
ABT earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday?
Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a strong rally in... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
Via Benzinga
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend. 
Via MarketBeat
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott Laboratories reported third-quarter 2024 sales of $10.64B, with Medical Devices leading 11.7% sales growth. Adjusted EPS of $1.21 beat analyst expectations. Full-year guidance was updated. 
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone
Via Benzinga
Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Columbus Day: Is Stock Market Open Today?
Investors should brace for a busy week with earnings reports from major companies. 
Via Benzinga
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.